lansoprazole has been researched along with Vomiting in 10 studies
Lansoprazole: A 2,2,2-trifluoroethoxypyridyl derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS. Lansoprazole is a racemic mixture of (R)- and (S)-isomers.
Vomiting: The forcible expulsion of the contents of the STOMACH through the MOUTH.
| Excerpt | Relevance | Reference |
|---|---|---|
| " In this open-label study, the effect of lansoprazole 30 mg qd and naproxen 500 mg bid on the pharmacokinetic profile of methotrexate was investigated." | 6.71 | Coadministration of lansoprazole and naproxen does not affect the pharmacokinetic profile of methotrexate in adult patients with rheumatoid arthritis. ( Amer, F; Andhivarothai, N; Kukulka, MJ; Vakily, M, 2005) |
| "Although bismuth was both the first drug shown to alter the natural history of peptic ulcer disease and also a constituent of the first very effective eradication regimens, it has been excluded from the newer regimens, despite its safety and low cost, in favour of two antibiotics." | 5.08 | Bismuth-containing single-antibiotic 1-week triple therapy for Helicobacter pylori eradication. ( Scott, BB, 1998) |
| " Proton pump inhibitor (PPI) use in EoE does not lead to histologic improvement; however, the long-term use of PPI on symptoms and prevention of complications has not been evaluated." | 2.77 | Conservative long-term treatment of children with eosinophilic esophagitis. ( Edelman, M; Lai, J; Levine, J; Schuval, SJ, 2012) |
| "Clarithromycin resistance was indirectly assessed by the (13)C-urea breath test, with a post-treatment value cut-off point at 15." | 2.73 | Levofloxacin-containing triple therapy to eradicate the persistent H. pylori after a failed conventional triple therapy. ( Chang, WL; Chen, WY; Cheng, HC; Sheu, BS; Wu, JJ; Yang, HB, 2007) |
| " In this open-label study, the effect of lansoprazole 30 mg qd and naproxen 500 mg bid on the pharmacokinetic profile of methotrexate was investigated." | 2.71 | Coadministration of lansoprazole and naproxen does not affect the pharmacokinetic profile of methotrexate in adult patients with rheumatoid arthritis. ( Amer, F; Andhivarothai, N; Kukulka, MJ; Vakily, M, 2005) |
| "To review the literature on the treatment of gastroesophageal reflux disease (GERD) with emphasis on pharmacological aspects." | 2.43 | Treatment of gastroesophageal reflux disease. ( Camargos, PA; Guimarães, EV; Marguet, C, 2006) |
| "Omeprazole was used in 90% of the patients; lansoprazole, in 7%." | 1.34 | Characteristics of children receiving proton pump inhibitors continuously for up to 11 years duration. ( El-Serag, HB; Hassall, E; Kerr, W, 2007) |
| "Cough was significantly less severe in NEE adolescents than in younger children." | 1.33 | Presenting symptoms of nonerosive and erosive esophagitis in pediatric patients. ( Amer, F; Chiu, YL; Gupta, SK; Hassall, E; Heyman, MB, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (10.00) | 18.2507 |
| 2000's | 6 (60.00) | 29.6817 |
| 2010's | 3 (30.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kajihara, Y | 1 |
| Parrish, DW | 1 |
| Sharma, S | 1 |
| Kumar, S | 1 |
| Levine, J | 1 |
| Lai, J | 1 |
| Edelman, M | 1 |
| Schuval, SJ | 1 |
| Vakily, M | 1 |
| Amer, F | 2 |
| Kukulka, MJ | 1 |
| Andhivarothai, N | 1 |
| Gupta, SK | 1 |
| Hassall, E | 2 |
| Chiu, YL | 1 |
| Heyman, MB | 1 |
| Guimarães, EV | 1 |
| Marguet, C | 1 |
| Camargos, PA | 1 |
| Kerr, W | 1 |
| El-Serag, HB | 1 |
| Cheng, HC | 1 |
| Chang, WL | 1 |
| Chen, WY | 1 |
| Yang, HB | 1 |
| Wu, JJ | 1 |
| Sheu, BS | 1 |
| Reynolds, EW | 1 |
| Kinnard, TB | 1 |
| Kriss, VM | 1 |
| Perman, JA | 1 |
| Scott, BB | 1 |
1 review available for lansoprazole and Vomiting
| Article | Year |
|---|---|
Treatment of gastroesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abdominal Pain; Adolescent; Adult; Anti-Ulcer Agents; Barre | 2006 |
4 trials available for lansoprazole and Vomiting
| Article | Year |
|---|---|
Conservative long-term treatment of children with eosinophilic esophagitis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Child; Child, Preschool; Deglutition Disorders; Endoscopy; | 2012 |
Coadministration of lansoprazole and naproxen does not affect the pharmacokinetic profile of methotrexate in adult patients with rheumatoid arthritis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Aged; Anti-Inflammatory Agents | 2005 |
Levofloxacin-containing triple therapy to eradicate the persistent H. pylori after a failed conventional triple therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; | 2007 |
Bismuth-containing single-antibiotic 1-week triple therapy for Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abdominal Pain; Adolescent; Adult; Aged; Aged, 80 and over; | 1998 |
5 other studies available for lansoprazole and Vomiting
| Article | Year |
|---|---|
An elderly woman with progressive odynophagia, epigastralgia and nausea.
Topics: Abdominal Pain; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Endoscopy, Digesti | 2018 |
Is the consistency more important than the ingredients for steroid treatment in eosinophilic esophagitis?
Topics: Budesonide; Child, Preschool; Combined Modality Therapy; Diet Therapy; Eosinophilic Esophagitis; Eos | 2014 |
Presenting symptoms of nonerosive and erosive esophagitis in pediatric patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abdominal Pain; Adolescent; Anorexia; Anti-Ulcer Agents; Ch | 2006 |
Characteristics of children receiving proton pump inhibitors continuously for up to 11 years duration.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Age Distribution; Child; Child, Preschool; Cohort Studies; | 2007 |
Superior mesenteric artery syndrome: an uncommon cause of feeding intolerance in infancy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Dexamethasone; Enteral Nutrition; Gastroesophageal Reflux; | 2008 |